Noting that in 2017, GlaxoSmithKline withdrew the glucagon-like peptide 1 (GLP-1) receptor agonist albiglutide for commercial reasons, Adrian F. Hernandez, MD, from the Duke University School of ...

Albiglutide (trade name Eperzan) has been approved since March 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

Albiglutide therapy as an adjunct to standard type 2 diabetes treatment reduced cardiovascular event incidence among older adults. Albiglutide, a long-acting glucagon-like peptide-1 receptor ...

June 12, 2012 (Philadelphia, Pennsylvania) — Once-weekly albiglutide has a more favorable tolerability profile than once-daily liraglutide, with similar effectiveness; however, albiglutide did ...

New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) and published in The Lancet shows that treatment with albiglutide (a type of drug ...

Albiglutide (TanzeumTM/Eperzan®) is a glucagon-like peptide-1 receptor agonist (GLP-1), a biological product for the treatment of type 2 diabetes, administered once-weekly using an injector pen ...

Albiglutide is not approved for use anywhere in the world. The CHMP positive opinion is based on an evaluation of a comprehensive global programme of studies involving over 5,000 patients.

A new once-weekly injectable glucagonlike peptide 1 (GLP-1) receptor agonist, albiglutide (Eperzan, GlaxoSmithKline), has been approved in the European Union for the treatment of type 2 diabetes.

The study, known as Harmony 7, is a head-to-head study designed to compare albiglutide, an investigational once weekly glucagon-like peptide-1 (GLP-1) agonist, to once-a-day liraglutide ...

Study data for a combination with metformin show a hint of a minor added benefit because symptomatic hypoglycemia occurs less frequently, experts report after an investigation. Albiglutide (trade ...